IGFBP1 is One of 10 Metabolic Factors Predicting Recurrence Free Survival in Gastric Cancer and Promotes Cancer Progression via ZFX-IGFBP1 Axis [0.03%]
IGFBP1是胃癌预后相关的10个代谢因子之一并通过ZFX-IGFBP1轴促进胃癌进展
Hui Liu,Yongming Huang,Guanghua Fu et al.
Hui Liu et al.
Introduction: Metabolism-related genes (MRGs) critically influence cancer prognosis, yet their role in gastric carcinoma (GC) remains poorly understood. M...
MAM Domain Containing 2 (MAMDC2) Affects Invasion and Metastasis of Human Gastric Cancer [0.03%]
含MAM结构域蛋白2(MAMDC2)影响人胃癌浸润和转移
Jiaofeng Shen,Guangyu Gao,Songtao Liu
Jiaofeng Shen
Background: Gastric cancer (GC) is the fifth most prevalent cancer worldwide and the fourth leading cause of cancer-related mortality. MAM Domain Containing 2 (MAMDC2) has been involved in many cancers. However, the impac...
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes [0.03%]
结合血浆肿瘤DNA和临床特征评估转移性雄激素耐药前列腺癌患者紫杉烷治疗预后评分的验证研究
Nicole Brighi,Giuseppe Schepisi,Vincenza Conteduca et al.
Nicole Brighi et al.
Purpose: There is an urgent need of biomarkers to personalize metastatic castration-resistant prostate cancer (mCRPC) treatment. A new prognostic model described by our group combines molecular characteristics (ptDNA leve...
CXCL11: A Novel Biomarker in Colorectal Cancer as Metastasis Predictor [0.03%]
CXCL11：一种新的结直肠癌转移预测生物标志物
Riyadi Wibowo,Yunia Sribudiani,Kiki Lukman et al.
Riyadi Wibowo et al.
Objective: CXCL11 (C-X-C motif chemokine ligand 11) encodes a chemokine, a small signaling protein involved in immune and inflammatory responses. This study aims to evaluate the association between CXCL11 gene expression ...
Risk of Residual Axillary Lymph Node Macrometastasis in Early Breast Cancer PATIENTS with One Positive Macrometastasis Sentinel Lymph Node [0.03%]
单枚宏转移腋窝SENTINEL淋巴结早期乳腺癌患者残余腋窝淋巴结宏转移风险分析
Dao-Yong Liu,Yun Zhu,Qiang Xie et al.
Dao-Yong Liu et al.
Objective: To investigate the risk factors for residual axillary lymph node macro-metastasis in early-stage breast cancer patients with a single macrometastasis sentinel lymph node (SLN). ...
lncSLERT Promotes Liver Metastasis in Colorectal Cancer by Down-Regulating HUNK Expression via RBM15-Mediated m6A Modification [0.03%]
lncSLERT通过RBM15介导的m6A修饰促进结直肠癌肝转移的新机制研究(HUNK下调)
Lin Wang,Liming Zhao,Jialiang Liu et al.
Lin Wang et al.
Background: Metastasis is a hallmark of cancer and the leading cause of cancer-related mortality. However, the mechanism underlying liver metastasis in colorectal cancer (CRC) remains incompletely understood. This study e...
Targeting the Inactive Conformation of the Epidermal Growth Factor Receptor Identifies EG31: A Novel Small Molecule Inhibitor Effective Against Normal and 5-Fluorouracil-Resistant Triple Negative Breast Cancer Cells [0.03%]
针对表皮生长因子受体非活性构象的靶向鉴定EG31：一种新型小分子抑制剂可有效用于三阴乳腺癌细胞及氟尿嘧啶耐药性三阴乳腺癌细胞
Hassan M Otifi
Hassan M Otifi
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors, making it difficult to treat with targeted therapies. ...
Measles Virus-Based Genetic Modifications: Progress in Hematological Malignancy Treatment [0.03%]
基于麻疹病毒的遗传学改造及其在血液系统恶性肿瘤治疗中的进展
Siqian Lan,Zhengyan Zhao,Zhixu He
Siqian Lan
With the enhancement of public living standards and health awareness, demands for high-quality treatment with hematological malignancies are increasing, correspondingly. However, since significant adverse events have been found associated w...
Erratum: Efficacy and Safety of Combined PD-1 Inhibitor with Induction Chemotherapy Followed by IMRT Plus Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Analysis [Corrigendum] [0.03%]
程序性死亡受体1抑制剂联合诱导化疗序贯同期放化疗±尼莫单抗治疗局部晚期鼻咽癌的疗效及安全性：一项回顾性分析 corrections
[This corrects the article DOI: 10.2147/OTT.S503674.]. © 2025 Chen et al.
Published Erratum
OncoTargets and therapy. 2025 Apr 23:18:603-604. DOI:10.2147/OTT.S533353 2025
Therapeutic Potential of Datopotamab Deruxtecan in the Treatment of Advanced Non-Small Cell Lung Cancer: Evidence to Date [0.03%]
Datopotamab德鲁替康治疗晚期非小细胞肺癌的治疗潜力：迄今为止的证据
Maya Gogtay,Nikhila Aimalla,Ram Prakash Thirugnanasambandam et al.
Maya Gogtay et al.
Lung cancer is the leading cause of global cancer mortality, accounting for an estimated 2 million diagnoses and 1.8 million deaths annually. Treatment choices for non-small cell lung cancer include surgery, radiation therapy, chemotherapy,...